Cancel
Arcus Biosciences
See Linkedin
Arcus Biosciences Employees
9 people indexed:
-
89pv54x@p047yv1p.f34 Sign up to see email
-
l74kd@9xw84yhz.d5j Sign up to see email
-
1g.5.6w6v8f@9zv3gpx0.736 Sign up to see email
-
7f09k3y59@x282jff3.0pn Sign up to see email
-
893vv4qk@w6998kqk.3n5 Sign up to see email
-
1pt7k31dp@6we2w6de.pqp Sign up to see email
-
vf868@dd5x0z9z.kyt Sign up to see email
-
268yxj@p9g8896f.w3j Sign up to see email
-
9twktv0k@0k26x9ft.dp0 Sign up to see email
Arcus Biosciences Company Information
Arcus Biosciences develops differentiated molecules and combination therapies aimed at treating cancer. Its clinical pipeline includes investigational molecules such as domvanalimab, etrumadenant, and zimberelimab. The company engages in global clinical trials for these products, targeting various cancer types including lung, gastrointestinal, and kidney cancers. Arcus Biosciences investigates molecules that target mechanisms like TIGIT, PD-1, CD39, and AXL. The company has a 10-year partnership with Gilead Sciences focusing on cancer immunotherapies and collaborates with Taiho Pharmaceutical for development in Japan and other Asian territories. Additionally, Arcus offers an Expanded Access Program for its investigational therapies. The company is headquartered in Hayward, California, with additional facilities in Brisbane, California.
Report inaccurate information
Report inaccurate information
